APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hip Osteoarthritis Pain Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hip Osteoarthritis Pain Medicine Market Outlook and Growth Opportunities 2026

Report ID 173998630421 December 2025209 pages

Choose your research edition.

Industry ResearchHip Osteoarthritis Pain Medicine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Hip Osteoarthritis Pain Medicine Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Hip Osteoarthritis Pain Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hip Osteoarthritis Pain Medicine Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Hip Osteoarthritis Pain Medicine Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Hip Osteoarthritis Pain Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hip Osteoarthritis Pain Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hip Osteoarthritis Pain Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hip Osteoarthritis Pain Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hip Osteoarthritis Pain Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hip Osteoarthritis Pain Medicine market include Abbott, TEVA, Sanofi, Johnson and Johnson, Novartis, Mylan, Eli Lilly, Pfizer and Hengrui Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hip Osteoarthritis Pain Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hip Osteoarthritis Pain Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hip Osteoarthritis Pain Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hip Osteoarthritis Pain Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Hip Osteoarthritis Pain Medicine Segment by Company

Abbott

TEVA

Sanofi

Johnson and Johnson

Novartis

Mylan

Eli Lilly

Pfizer

Hengrui Pharmaceutical

GlaxoSmithKline

Daiichi Sankyo

Bayer

Tide Pharmaceutical

Iroko Pharmaceuticals

Horizon Pharma

Astellas Pharma

Almatica Pharma

Abiogen Pharma

Hip Osteoarthritis Pain Medicine Segment by Type

Injection

External

Oral

Hip Osteoarthritis Pain Medicine Segment by Application

Medical Care

Personal Care

Hip Osteoarthritis Pain Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hip Osteoarthritis Pain Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hip Osteoarthritis Pain Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hip Osteoarthritis Pain Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Hip Osteoarthritis Pain Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hip Osteoarthritis Pain Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hip Osteoarthritis Pain Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hip Osteoarthritis Pain Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hip Osteoarthritis Pain Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hip Osteoarthritis Pain Medicine industry.

Chapter 3: Detailed analysis of Hip Osteoarthritis Pain Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hip Osteoarthritis Pain Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hip Osteoarthritis Pain Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hip Osteoarthritis Pain Medicine Industry Trends Table 2. Hip Osteoarthritis Pain Medicine Industry Drivers Table 3. Hip Osteoarthritis Pain Medicine Industry Opportunities and Challenges Table 4. Hip Osteoarthritis Pain Medicine Industry Restraints Table 5. Global Hip Osteoarthritis Pain Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hip Osteoarthritis Pain Medicine Revenue Share by Company (2021-2026) Table 7. Global Hip Osteoarthritis Pain Medicine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Company (2021-2026) Table 9. Global Hip Osteoarthritis Pain Medicine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Hip Osteoarthritis Pain Medicine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hip Osteoarthritis Pain Medicine Key Company Manufacturing Base & Headquarters Table 12. Global Hip Osteoarthritis Pain Medicine Company, Product Type & Application Table 13. Global Hip Osteoarthritis Pain Medicine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hip Osteoarthritis Pain Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection Table 18. Significant Companies of External Table 19. Significant Companies of Oral Table 20. Global Hip Osteoarthritis Pain Medicine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Hip Osteoarthritis Pain Medicine Sales Volume by Type (2021-2026) & (k units) Table 22. Global Hip Osteoarthritis Pain Medicine Sales Volume by Type (2027-2032) & (k units) Table 23. Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Type (2021-2026) Table 24. Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Type (2027-2032) Table 25. Global Hip Osteoarthritis Pain Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Hip Osteoarthritis Pain Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Hip Osteoarthritis Pain Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Type (2021-2026) Table 29. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Medical Care Table 31. Significant Companies of Personal Care Table 32. Global Hip Osteoarthritis Pain Medicine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Hip Osteoarthritis Pain Medicine Sales Volume by Application (2021-2026) & (k units) Table 34. Global Hip Osteoarthritis Pain Medicine Sales Volume by Application (2027-2032) & (k units) Table 35. Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Application (2021-2026) Table 36. Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Application (2027-2032) Table 37. Global Hip Osteoarthritis Pain Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hip Osteoarthritis Pain Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Hip Osteoarthritis Pain Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Application (2021-2026) Table 41. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Application (2027-2032) Table 42. Global Hip Osteoarthritis Pain Medicine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Hip Osteoarthritis Pain Medicine Sales by Region (2021-2026) & (k units) Table 44. Global Hip Osteoarthritis Pain Medicine Sales Market Share by Region (2021-2026) Table 45. Global Hip Osteoarthritis Pain Medicine Sales by Region (2027-2032) & (k units) Table 46. Global Hip Osteoarthritis Pain Medicine Sales Market Share by Region (2027-2032) Table 47. Global Hip Osteoarthritis Pain Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Hip Osteoarthritis Pain Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Region (2021-2026) Table 50. Global Hip Osteoarthritis Pain Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Region (2027-2032) Table 52. Global Hip Osteoarthritis Pain Medicine Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Hip Osteoarthritis Pain Medicine Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Hip Osteoarthritis Pain Medicine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Hip Osteoarthritis Pain Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Hip Osteoarthritis Pain Medicine Sales by Country (2021-2026) & (k units) Table 57. Global Hip Osteoarthritis Pain Medicine Sales Market Share by Country (2021-2026) Table 58. Global Hip Osteoarthritis Pain Medicine Sales by Country (2027-2032) & (k units) Table 59. Global Hip Osteoarthritis Pain Medicine Sales Market Share by Country (2027-2032) Table 60. Global Hip Osteoarthritis Pain Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Hip Osteoarthritis Pain Medicine Sales Value Market Share by Country (2021-2026) Table 62. Global Hip Osteoarthritis Pain Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Hip Osteoarthritis Pain Medicine Sales Value Market Share by Country (2027-2032) Table 64. Abbott Company Information Table 65. Abbott Business Overview Table 66. Abbott Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Abbott Hip Osteoarthritis Pain Medicine Product Portfolio Table 68. Abbott Recent Development Table 69. TEVA Company Information Table 70. TEVA Business Overview Table 71. TEVA Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. TEVA Hip Osteoarthritis Pain Medicine Product Portfolio Table 73. TEVA Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sanofi Hip Osteoarthritis Pain Medicine Product Portfolio Table 78. Sanofi Recent Development Table 79. Johnson and Johnson Company Information Table 80. Johnson and Johnson Business Overview Table 81. Johnson and Johnson Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Johnson and Johnson Hip Osteoarthritis Pain Medicine Product Portfolio Table 83. Johnson and Johnson Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Novartis Hip Osteoarthritis Pain Medicine Product Portfolio Table 88. Novartis Recent Development Table 89. Mylan Company Information Table 90. Mylan Business Overview Table 91. Mylan Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Mylan Hip Osteoarthritis Pain Medicine Product Portfolio Table 93. Mylan Recent Development Table 94. Eli Lilly Company Information Table 95. Eli Lilly Business Overview Table 96. Eli Lilly Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Eli Lilly Hip Osteoarthritis Pain Medicine Product Portfolio Table 98. Eli Lilly Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Pfizer Hip Osteoarthritis Pain Medicine Product Portfolio Table 103. Pfizer Recent Development Table 104. Hengrui Pharmaceutical Company Information Table 105. Hengrui Pharmaceutical Business Overview Table 106. Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio Table 108. Hengrui Pharmaceutical Recent Development Table 109. GlaxoSmithKline Company Information Table 110. GlaxoSmithKline Business Overview Table 111. GlaxoSmithKline Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. GlaxoSmithKline Hip Osteoarthritis Pain Medicine Product Portfolio Table 113. GlaxoSmithKline Recent Development Table 114. Daiichi Sankyo Company Information Table 115. Daiichi Sankyo Business Overview Table 116. Daiichi Sankyo Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Daiichi Sankyo Hip Osteoarthritis Pain Medicine Product Portfolio Table 118. Daiichi Sankyo Recent Development Table 119. Bayer Company Information Table 120. Bayer Business Overview Table 121. Bayer Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Bayer Hip Osteoarthritis Pain Medicine Product Portfolio Table 123. Bayer Recent Development Table 124. Tide Pharmaceutical Company Information Table 125. Tide Pharmaceutical Business Overview Table 126. Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio Table 128. Tide Pharmaceutical Recent Development Table 129. Iroko Pharmaceuticals Company Information Table 130. Iroko Pharmaceuticals Business Overview Table 131. Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Product Portfolio Table 133. Iroko Pharmaceuticals Recent Development Table 134. Horizon Pharma Company Information Table 135. Horizon Pharma Business Overview Table 136. Horizon Pharma Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Horizon Pharma Hip Osteoarthritis Pain Medicine Product Portfolio Table 138. Horizon Pharma Recent Development Table 139. Astellas Pharma Company Information Table 140. Astellas Pharma Business Overview Table 141. Astellas Pharma Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Astellas Pharma Hip Osteoarthritis Pain Medicine Product Portfolio Table 143. Astellas Pharma Recent Development Table 144. Almatica Pharma Company Information Table 145. Almatica Pharma Business Overview Table 146. Almatica Pharma Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Almatica Pharma Hip Osteoarthritis Pain Medicine Product Portfolio Table 148. Almatica Pharma Recent Development Table 149. Abiogen Pharma Company Information Table 150. Abiogen Pharma Business Overview Table 151. Abiogen Pharma Hip Osteoarthritis Pain Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Abiogen Pharma Hip Osteoarthritis Pain Medicine Product Portfolio Table 153. Abiogen Pharma Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Hip Osteoarthritis Pain Medicine Distributors List Table 157. Hip Osteoarthritis Pain Medicine Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Hip Osteoarthritis Pain Medicine Product Image Figure 2. Global Hip Osteoarthritis Pain Medicine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hip Osteoarthritis Pain Medicine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hip Osteoarthritis Pain Medicine Sales (2021-2032) & (k units) Figure 5. Global Hip Osteoarthritis Pain Medicine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Hip Osteoarthritis Pain Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection Image Figure 10. External Image Figure 11. Oral Image Figure 12. Global Hip Osteoarthritis Pain Medicine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Hip Osteoarthritis Pain Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Type (2021-2032) Figure 15. Global Hip Osteoarthritis Pain Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Hip Osteoarthritis Pain Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Type (2021-2032) Figure 18. Medical Care Image Figure 19. Personal Care Image Figure 20. Global Hip Osteoarthritis Pain Medicine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Hip Osteoarthritis Pain Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Application (2021-2032) Figure 23. Global Hip Osteoarthritis Pain Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hip Osteoarthritis Pain Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Application (2021-2032) Figure 26. Global Hip Osteoarthritis Pain Medicine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Hip Osteoarthritis Pain Medicine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Hip Osteoarthritis Pain Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Hip Osteoarthritis Pain Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Hip Osteoarthritis Pain Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Hip Osteoarthritis Pain Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Hip Osteoarthritis Pain Medicine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Hip Osteoarthritis Pain Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Hip Osteoarthritis Pain Medicine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Hip Osteoarthritis Pain Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Hip Osteoarthritis Pain Medicine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Hip Osteoarthritis Pain Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Hip Osteoarthritis Pain Medicine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Hip Osteoarthritis Pain Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Hip Osteoarthritis Pain Medicine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Hip Osteoarthritis Pain Medicine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • External
  • Oral
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Abbott
  • TEVA
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Mylan
  • Eli Lilly
  • Pfizer
  • Hengrui Pharmaceutical
  • GlaxoSmithKline
  • Daiichi Sankyo
  • Bayer
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Horizon Pharma
  • Astellas Pharma
  • Almatica Pharma
  • Abiogen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hip Osteoarthritis Pain Medicine Sales Value (2021-2032)
  4. 1.2.2 Global Hip Osteoarthritis Pain Medicine Sales Volume (2021-2032)
  5. 1.2.3 Global Hip Osteoarthritis Pain Medicine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hip Osteoarthritis Pain Medicine Market Dynamics
  1. 2.1 Hip Osteoarthritis Pain Medicine Industry Trends
  2. 2.2 Hip Osteoarthritis Pain Medicine Industry Drivers
  3. 2.3 Hip Osteoarthritis Pain Medicine Industry Opportunities and Challenges
  4. 2.4 Hip Osteoarthritis Pain Medicine Industry Restraints
3 Hip Osteoarthritis Pain Medicine Market by Company
  1. 3.1 Global Hip Osteoarthritis Pain Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Hip Osteoarthritis Pain Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Hip Osteoarthritis Pain Medicine Sales Volume by Company (2021-2026)
  4. 3.4 Global Hip Osteoarthritis Pain Medicine Average Price by Company (2021-2026)
  5. 3.5 Global Hip Osteoarthritis Pain Medicine Company Ranking (2024-2026)
  6. 3.6 Global Hip Osteoarthritis Pain Medicine Company Manufacturing Base and Headquarters
  7. 3.7 Global Hip Osteoarthritis Pain Medicine Company Product Type and Application
  8. 3.8 Global Hip Osteoarthritis Pain Medicine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hip Osteoarthritis Pain Medicine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hip Osteoarthritis Pain Medicine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hip Osteoarthritis Pain Medicine Market by Type
  1. 4.1 Hip Osteoarthritis Pain Medicine Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 External
  4. 4.1.3 Oral
  5. 4.2 Global Hip Osteoarthritis Pain Medicine Sales Volume by Type
  6. 4.2.1 Global Hip Osteoarthritis Pain Medicine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Hip Osteoarthritis Pain Medicine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Hip Osteoarthritis Pain Medicine Sales Value by Type
  10. 4.3.1 Global Hip Osteoarthritis Pain Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Hip Osteoarthritis Pain Medicine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Hip Osteoarthritis Pain Medicine Sales Value Share by Type (2021-2032)
5 Hip Osteoarthritis Pain Medicine Market by Application
  1. 5.1 Hip Osteoarthritis Pain Medicine Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Hip Osteoarthritis Pain Medicine Sales Volume by Application
  5. 5.2.1 Global Hip Osteoarthritis Pain Medicine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hip Osteoarthritis Pain Medicine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Hip Osteoarthritis Pain Medicine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Hip Osteoarthritis Pain Medicine Sales Value by Application
  9. 5.3.1 Global Hip Osteoarthritis Pain Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Hip Osteoarthritis Pain Medicine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Hip Osteoarthritis Pain Medicine Sales Value Share by Application (2021-2032)
6 Hip Osteoarthritis Pain Medicine Regional Sales and Value Analysis
  1. 6.1 Global Hip Osteoarthritis Pain Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hip Osteoarthritis Pain Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Hip Osteoarthritis Pain Medicine Sales by Region: 2021-2026
  4. 6.2.2 Global Hip Osteoarthritis Pain Medicine Sales by Region (2027-2032)
  5. 6.3 Global Hip Osteoarthritis Pain Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hip Osteoarthritis Pain Medicine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hip Osteoarthritis Pain Medicine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hip Osteoarthritis Pain Medicine Sales Value by Region (2027-2032)
  9. 6.5 Global Hip Osteoarthritis Pain Medicine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hip Osteoarthritis Pain Medicine Sales Value (2021-2032)
  12. 6.6.2 North America Hip Osteoarthritis Pain Medicine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hip Osteoarthritis Pain Medicine Sales Value (2021-2032)
  15. 6.7.2 Europe Hip Osteoarthritis Pain Medicine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hip Osteoarthritis Pain Medicine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hip Osteoarthritis Pain Medicine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hip Osteoarthritis Pain Medicine Sales Value (2021-2032)
  21. 6.9.2 South America Hip Osteoarthritis Pain Medicine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hip Osteoarthritis Pain Medicine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hip Osteoarthritis Pain Medicine Sales Value Share by Country, 2025 VS 2032
7 Hip Osteoarthritis Pain Medicine Country-level Sales and Value Analysis
  1. 7.1 Global Hip Osteoarthritis Pain Medicine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hip Osteoarthritis Pain Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hip Osteoarthritis Pain Medicine Sales by Country (2021-2032)
  4. 7.3.1 Global Hip Osteoarthritis Pain Medicine Sales by Country (2021-2026)
  5. 7.3.2 Global Hip Osteoarthritis Pain Medicine Sales by Country (2027-2032)
  6. 7.4 Global Hip Osteoarthritis Pain Medicine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hip Osteoarthritis Pain Medicine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hip Osteoarthritis Pain Medicine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hip Osteoarthritis Pain Medicine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hip Osteoarthritis Pain Medicine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hip Osteoarthritis Pain Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Hip Osteoarthritis Pain Medicine Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 TEVA
  8. 8.2.1 TEVA Company Information
  9. 8.2.2 TEVA Business Overview
  10. 8.2.3 TEVA Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 TEVA Hip Osteoarthritis Pain Medicine Product Portfolio
  12. 8.2.5 TEVA Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Hip Osteoarthritis Pain Medicine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Hip Osteoarthritis Pain Medicine Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Hip Osteoarthritis Pain Medicine Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Hip Osteoarthritis Pain Medicine Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Hip Osteoarthritis Pain Medicine Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Hip Osteoarthritis Pain Medicine Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Hengrui Pharmaceutical
  50. 8.9.1 Hengrui Pharmaceutical Company Information
  51. 8.9.2 Hengrui Pharmaceutical Business Overview
  52. 8.9.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio
  54. 8.9.5 Hengrui Pharmaceutical Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Hip Osteoarthritis Pain Medicine Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Hip Osteoarthritis Pain Medicine Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Hip Osteoarthritis Pain Medicine Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 Tide Pharmaceutical
  74. 8.13.1 Tide Pharmaceutical Company Information
  75. 8.13.2 Tide Pharmaceutical Business Overview
  76. 8.13.3 Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio
  78. 8.13.5 Tide Pharmaceutical Recent Developments
  79. 8.14 Iroko Pharmaceuticals
  80. 8.14.1 Iroko Pharmaceuticals Company Information
  81. 8.14.2 Iroko Pharmaceuticals Business Overview
  82. 8.14.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Product Portfolio
  84. 8.14.5 Iroko Pharmaceuticals Recent Developments
  85. 8.15 Horizon Pharma
  86. 8.15.1 Horizon Pharma Company Information
  87. 8.15.2 Horizon Pharma Business Overview
  88. 8.15.3 Horizon Pharma Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Horizon Pharma Hip Osteoarthritis Pain Medicine Product Portfolio
  90. 8.15.5 Horizon Pharma Recent Developments
  91. 8.16 Astellas Pharma
  92. 8.16.1 Astellas Pharma Company Information
  93. 8.16.2 Astellas Pharma Business Overview
  94. 8.16.3 Astellas Pharma Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Astellas Pharma Hip Osteoarthritis Pain Medicine Product Portfolio
  96. 8.16.5 Astellas Pharma Recent Developments
  97. 8.17 Almatica Pharma
  98. 8.17.1 Almatica Pharma Company Information
  99. 8.17.2 Almatica Pharma Business Overview
  100. 8.17.3 Almatica Pharma Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Almatica Pharma Hip Osteoarthritis Pain Medicine Product Portfolio
  102. 8.17.5 Almatica Pharma Recent Developments
  103. 8.18 Abiogen Pharma
  104. 8.18.1 Abiogen Pharma Company Information
  105. 8.18.2 Abiogen Pharma Business Overview
  106. 8.18.3 Abiogen Pharma Hip Osteoarthritis Pain Medicine Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Abiogen Pharma Hip Osteoarthritis Pain Medicine Product Portfolio
  108. 8.18.5 Abiogen Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hip Osteoarthritis Pain Medicine Value Chain Analysis
  2. 9.1.1 Hip Osteoarthritis Pain Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hip Osteoarthritis Pain Medicine Sales Mode & Process
  6. 9.2 Hip Osteoarthritis Pain Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hip Osteoarthritis Pain Medicine Distributors
  9. 9.2.3 Hip Osteoarthritis Pain Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst